We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.


17. September 2014

Geistlich Pharma AG wins the 2014 IHZ prize for innovation

Geistlich Pharma wins the 2014 prize for innovation from the Chamber of Industry and Commerce of Central Switzerland (IHZ). The IHZ rated the products Geistlich Mucograft® and Geistlich Mucograft® Seal as an outstanding achievement.

Paul Note, CEO of Geistlich Pharma, is highly delighted. He summarises the benefits and achievements of the pioneering products: "Geistlich Mucograft® and Geistlich Mucograft® Seal save the patient considerable pain." These products, the first to be developed worldwide for the regeneration of gingiva, are collagen matrices. They offer an alternative to conventional transplants from the patient's palate. The two products are used primarily to cover exposed root surfaces and to cover cavities after tooth removal. For the patient, they offer a shorter duration of operation, reduced risk of complications and less pain also after the operation. With these two developments, Geistlich Pharma is underlining its role as an innovation leader in regenerative dental medicine.    


Pioneering product as the result of long-standing expertise?

What is the success of Geistlich Pharma based on? At Geistlich Pharma, everything comes from one source: from research and development to production and sales. The achievement awarded the 2014 prize for innovation is based both on long-standing expertise and on international collaboration with researchers and clinicians. As a Swiss family-owned company, Geistlich Pharma pursues a sustainable, scientific concept in research and development. "Either you are a pioneer, or you stand still," explains Dr. Terance Hart, Chief Scientific Officer. Geistlich Pharma wins the IHZ prize for innovation for the third time (after 1994 and 2006).    


With its roots firmly in Switzerland

Geistlich Pharma looks back at a corporate history of more than 160 years and employs around 450 staff at its Central Swiss sites of Wolhusen and Root as well as at eight affiliates worldwide. The company is entirely family-owned.